


Topoisomerase II inhibitor 18

Cat. No.:	HY-162380
CAS No.:	2382959-65-9
Molecular Formula:	C ₂₀ H ₂₁ N ₃ OS
Molecular Weight:	351.47
Target:	Topoisomerase
Pathway:	Cell Cycle/DNA Damage
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Topoisomerase II inhibitor 18 (Compound IV) is a Quinoxaline derivative, which inhibits topoisomerase II with IC ₅₀ of 7.5 μM. Topoisomerase II inhibitor 18 inhibits proliferation, cell cycle at S phase and induces apoptosis in PC-3 cells. Topoisomerase II inhibitor 18 reveals antitumor activity against cancer ^[1] .																
IC₅₀ & Target	Topoisomerase II 7.5 μM (IC ₅₀)																
In Vitro	<p>Topoisomerase II inhibitor 18 (0-100 μM) inhibits proliferations of cancer cells PC-3 and HepG2 with IC₅₀s of 2.11 and 11.03 μM, without significant cytotoxicity in normal cells Vero (IC₅₀ is 23.12 μM)^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis^[1]</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Cell Line:</td> <td>PC-3</td> </tr> <tr> <td>Concentration:</td> <td>0-100 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 h</td> </tr> <tr> <td>Result:</td> <td>Increased levels of p53, cleaved caspase-3 and cleaved caspase-8. Decreased levels of Bcl-2.</td> </tr> </table> <p>Cell Proliferation Assay^[1]</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Cell Line:</td> <td>HepG2, PC-3</td> </tr> <tr> <td>Concentration:</td> <td>0-100 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 h</td> </tr> <tr> <td>Result:</td> <td>Inhibited proliferations of PC-3 and HepG2</td> </tr> </table>	Cell Line:	PC-3	Concentration:	0-100 μM	Incubation Time:	48 h	Result:	Increased levels of p53, cleaved caspase-3 and cleaved caspase-8. Decreased levels of Bcl-2.	Cell Line:	HepG2, PC-3	Concentration:	0-100 μM	Incubation Time:	48 h	Result:	Inhibited proliferations of PC-3 and HepG2
Cell Line:	PC-3																
Concentration:	0-100 μM																
Incubation Time:	48 h																
Result:	Increased levels of p53, cleaved caspase-3 and cleaved caspase-8. Decreased levels of Bcl-2.																
Cell Line:	HepG2, PC-3																
Concentration:	0-100 μM																
Incubation Time:	48 h																
Result:	Inhibited proliferations of PC-3 and HepG2																
In Vivo	Topoisomerase II inhibitor 18 (5 mg/kg, i.m. for 21 days) exhibits antitumor activity in Ehrlich solid tumor bearing albino mice, exhibits kidney protective efficacy ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.																

Animal Model:	Ehrlich solid tumor bearing albino mice ^[1]
Dosage:	5 mg/kg
Administration:	i.m. for 21 days
Result:	Inhibited tumor growth.

REFERENCES

[1]. Elsakka MEG, et al., A quinoxaline-based derivative exhibited potent and selective anticancer activity with apoptosis induction in PC-3 cells through Topo II inhibition. J Biomol Struct Dyn. 2024 Mar 14:1-19.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA